The development of advanced pharmaceuticals often relies on intricate chemical synthesis routes, where specific intermediates play pivotal roles. One such critical compound is (1S)-2-chloro-1-(3,4-difluorophenyl)-1-ethanol (CAS 1006376-60-8), an essential precursor in the manufacturing of Ticagrelor. Ticagrelor, a highly effective antiplatelet medication used to prevent thrombotic events in patients with acute coronary syndromes, owes its existence to the precise chemical transformations enabled by intermediates like this one.

The significance of (1S)-2-chloro-1-(3,4-difluorophenyl)-1-ethanol lies in its specific molecular structure and chirality. The '(1S)' designation refers to its specific spatial arrangement, which is crucial for the drug's biological activity. The 3,4-difluorophenyl group also contributes unique properties that are optimized for the drug's interaction with its target, the P2Y12 receptor. For pharmaceutical companies aiming to produce Ticagrelor efficiently and at scale, securing a consistent supply of high-purity (1S)-2-chloro-1-(3,4-difluorophenyl)-1-ethanol is a primary objective. This makes understanding the synthesis of (1S)-2-chloro-1-(3,4-difluorophenyl)-1-ethanol vital for process chemists and manufacturing teams.

As a key pharmaceutical intermediate, its availability impacts the entire supply chain for this life-saving medication. The process of creating this intermediate involves careful control over stereochemistry, ensuring that only the desired enantiomer is produced. This focus on precision is what makes it an invaluable organic synthesis building block. By sourcing this compound, manufacturers are essentially acquiring a foundational element for a complex therapeutic. The ability to readily buy (1S)-2-chloro-1-(3,4-difluorophenyl)-1-ethanol from reliable pharmaceutical intermediate suppliers ensures that the production of Ticagrelor can continue uninterrupted, ultimately benefiting patients worldwide.